Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
60%
Ph phase_3
2
40%

Phase Distribution

3

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Other(1)

Detailed Status

Completed4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (60.0%)
Phase 32 (40.0%)

Trials by Status

completed480%
unknown120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

A Study of a Candidate COVID-19 Vaccine (COV001)

NCT04324606
completedphase_3

A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

NCT05603052
completedphase_3

A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults

NCT05572879
completedphase_1

A Study of Intranasal ChAdOx1 nCOV-19

NCT04816019
unknownphase_1

COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection

NCT04444674

Clinical Trials (5)

Showing 5 of 5 trials
NCT04324606Phase 1

A Study of a Candidate COVID-19 Vaccine (COV001)

Completed
NCT05603052Phase 3

A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

Completed
NCT05572879Phase 3

A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults

Completed
NCT04816019Phase 1

A Study of Intranasal ChAdOx1 nCOV-19

Completed
NCT04444674Phase 1

COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection

Unknown

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5